Research graph
References from Membrane-associated HDAC11: A potential new therapeutic targeting compartment in cancer cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Histone deacetylases (HDACs): Evolution, specificity, role in transcriptional complexes, and pharmacological actionability
10.3390/genes11050556 · 2020 · External reference
Targeting histone deacetylases for cancer therapy: trends and challenges
10.1016/j.apsb.2023.02.007 · 2023 · External reference
Design and synthesis of piperidine hydroxamate scaffolds as novel HDAC inhibitors with apoptotic potential in human cervical cancer cells
10.2174/0115734064378681251128061500 · 2026 · External reference
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
10.1038/cddis.2013.9 · 2013 · External reference
Epigenetic mechanisms and therapeutic targeting across diverse malignancies
10.1080/17501911.2026.2667351 · 2026 · External reference
HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway
2026 · External reference
Mechanisms of HDACs in cancer development
2025 · External reference
Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives
10.3390/cancers13040634 · 2021 · External reference
The roles of histone deacetylases in the regulation of ovarian cancer metastasis
10.3390/ijms242015066 · 2023 · External reference
HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes
10.1111/febs.15895 · 2022 · External reference
Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase
10.1016/j.chembiol.2018.04.007 · 2018 · External reference
Histone deacetylase 11 is a fatty-acid deacylase
10.1021/acschembio.7b00942 · 2018 · External reference
shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer
2024 · External reference
HDAC11: a novel target for improved cancer therapy
2023 · External reference
Biological function and small molecule inhibitors of histone deacetylase 11
10.1016/j.ejmech.2024.116634 · 2024 · External reference
Advances and challenges of HDAC inhibitors in cancer therapeutics
10.1016/bs.acr.2018.02.006 · 2018 · External reference
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2
10.1038/s41598-020-61295-6 · 2020 · External reference
Histone deacetylase (HDAC) 11 inhibits matrix metalloproteinase (MMP) 3 expression to suppress colorectal cancer metastasis
10.7150/jca.66914 · 2022 · External reference
HDAC11 inhibition as a potential therapeutic strategy for AML: target identification, lead discovery, antitumor potency, and mechanism investigation
10.1021/acs.jmedchem.4c02550 · 2025 · External reference
HDAC11 is related to breast cancer prognosis and inhibits invasion and proliferation of breast cancer cells
2023 · External reference
Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes
10.1038/s41467-019-12222-5 · 2019 · External reference
Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis. Nan Fang Yi Ke Da Xue Xue Bao
2019 · External reference
Subcellular localization as a driver of protein function
10.1038/s41580-026-00947-3 · 2026 · External reference
Emerging magic bullet: subcellular organelle-targeted cancer therapy
10.1515/mr-2024-0044 · 2024 · External reference
Protein mislocalization: mechanisms, functions and clinical applications in cancer
2014 · External reference
The roles of nucleolin subcellular localization in cancer
10.1016/j.biochi.2015.03.023 · 2015 · External reference
HDAC11 is a novel regulator of fatty acid oxidative metabolism in skeletal muscle
10.1111/febs.15456 · 2021 · External reference
Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells
10.1158/0008-5472.can-08-3458 · 2009 · External reference
Functional divergence and structural changes of class IV histone deacetylases (HDACs) across the tree of life
10.1093/molbev/msag150 · 2026 · External reference
Substrate-Guided Development of HDAC11-Selective inhibitors featuring α-Amino amide zinc-binding groups
10.1021/acsomega.5c08195 · 2025 · External reference
Discovery of a hydroxamic acid-based HDAC11 isoform-selective inhibitor with oral Anti-AML potency
10.1021/acs.jmedchem.5c03107 · 2026 · External reference
Structural determinants of isoform selectivity in PI3K inhibitors
10.3390/biom9030082 · 2019 · External reference
Isoform-selective enzyme inhibitors by exploring pocket size according to the lock-and-key principle
10.1016/j.bpj.2020.08.037 · 2020 · External reference
Engineering protein-based therapeutics through structural and chemical design
10.1038/s41467-023-38039-x · 2023 · External reference
Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
10.1038/bjc.2011.9 · 2011 · External reference
Cell membrane as A promising therapeutic target: from materials design to biomedical applications
10.1002/anie.202400249 · 2024 · External reference
Membrane protein-regulated networks across human cancers
10.1038/s41467-019-10920-8 · 2019 · External reference
Development of antibody drug conjugates targeting epithelial membrane protein 2-highly expressed lung cancer
10.1038/s41419-025-08125-7 · 2025 · External reference
FT895 impairs mitochondrial function in malignant peripheral nerve sheath tumor cells
10.3390/ijms25010277 · 2023 · External reference
Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption
10.1038/s41420-024-02277-9 · 2024 · External reference
PROTAC-based HDAC degradation: a paradigm shift in targeted epigenetic therapies
10.1002/cmdc.202500203 · 2025 · External reference
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
10.1038/s41392-021-00572-w · 2021 · External reference
Exploring treatment options in cancer: tumor treatment strategies
10.1038/s41392-024-01856-7 · 2024 · External reference
PROTAC technology: opportunities and challenges
10.1021/acsmedchemlett.9b00597 · 2020 · External reference
PROTACs: current and future potential as a precision medicine strategy to combat cancer
10.1158/1535-7163.mct-23-0747 · 2024 · External reference
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
10.1186/s12943-021-01434-3 · 2022 · External reference
Proteolysis targeting Chimeras (PROTACs) in breast cancer therapy
10.1002/cmdc.202400267 · 2024 · External reference
Targeted protein degradation in the mitochondrial matrix and its application to chemical control of mitochondrial morphology
10.1039/d4sc03145h · 2024 · External reference
Mitochondrial protease targeting chimeras for mitochondrial matrix protein degradation
10.1021/jacs.3c03756 · 2023 · External reference
Targeted protein degradation in the transmembrane and extracellular space
10.1126/science.adx5094 · 2025 · External reference
Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression
10.1038/s41467-025-64426-7 · 2025 · External reference
Development of nanobody-based PROTAC (NbTAC) for ROR1 degradation by RNF149
2025 · External reference
Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance
10.1016/j.addr.2025.115755 · 2026 · External reference
